APMAP and neoplasm: These findings indicate that N‐glycosylation at APMAP‐N196 is significantly reduced in tumor tissues compared to NATs, and this reduction further promotes CRC progression, thereby providing new insights into CRC advancement and potential therapeutic interventions.